Biocon Biologics is planning to raise $950 million through overseas bonds
Biocon Biologics plans to raise $950 million dollars in overseas bond sales that will be managed by lenders including Standard Chartered Bank and HSBC, said three people aware of the fundraising. The funds will be used to refinance a large part of the $1.2-billion debt raised for the acquisition of Viatris Inc.’s biosimilars business, said … Read more
